Literature DB >> 7522071

In vivo biological activity of recombinant Der p II allergen of house-dust mite.

N R Lynch1, W R Thomas, Y Chua, N García, M C Di Prisco, R López.   

Abstract

The cDNA coding for one of the major allergens of Dermatophagoides pteronyssinus, Der p II, has been cloned and expressed in Escherichia coli as a fusion protein with glutathione S-transferase. The recombinant material (r Der p II) was tested in the skin of house-dust allergic patients, and was found to be almost as active as the purified native allergen (n Der p II) in stimulating immediate hypersensitivity reactions. The positivity to r Der p II in these patients, who were selected for their skin-test reactivity to house-dust extract (HDE) and whole mite extract (WME), was over 60%, and 80% of their sera contained detectable IgE antibody against the recombinant allergen. The level of specific IgE antibody against r Der p II was a mean of 40% of that against WME in the sera of patients who were skin test positive to both allergen preparations. In contrast to the house-dust allergic patients, none of a group of allergic patients whose clinical history did not implicate house dust, and who were skin test negative to HDE or WME, were positive to r Der p II. Of interest was the observation that only 37% of a group of subjects who were skin test positive to HDE and WME, but who reported no clinical history of allergic disease upon natural exposure to house dust, reacted to r Der p II. These results demonstrate the biological activity of r Der p II, and indicate, in persons skin test positive to house-dust mite extract, an association between reactivity to Der p II and the manifestation of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522071     DOI: 10.1159/000236805

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

1.  Characterization of an immunomodulatory Der p 2-FIP-fve fusion protein produced in transformed rice suspension cell culture.

Authors:  Chin-Fen Su; I-Chun Kuo; Peng-Wen Chen; Chiung-Hui Huang; See Voon Seow; Kaw Yan Chua; Su-May Yu
Journal:  Transgenic Res       Date:  2011-05-10       Impact factor: 2.788

2.  Design, production and immunomodulatory potency of a novel allergen bioparticle.

Authors:  Véronique Gomord; Virginie Stordeur; Anne-Catherine Fitchette; Elizabeth D Fixman; Guy Tropper; Lorna Garnier; Réjean Desgagnes; Sébastien Viel; Julie Couillard; Guillaume Beauverger; Sylvain Trepout; Brian J Ward; Ronald van Ree; Loic Faye; Louis-P Vézina
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

Review 3.  Recombinant allergen-based provocation testing.

Authors:  Verena Niederberger; Julia Eckl-Dorna; Gabrielle Pauli
Journal:  Methods       Date:  2013-08-03       Impact factor: 3.608

Review 4.  Single recombinant and purified major allergens and peptides: How they are made and how they change allergy diagnosis and treatment.

Authors:  Mirela Curin; Viktoriya Garib; Rudolf Valenta
Journal:  Ann Allergy Asthma Immunol       Date:  2017-09       Impact factor: 6.347

Review 5.  Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?

Authors:  Rudolf Valenta; Alexander Karaulov; Verena Niederberger; Yury Zhernov; Olga Elisyutina; Raffaela Campana; Margarete Focke-Tejkl; Mirela Curin; Leyla Namazova-Baranova; Jiu-Yao Wang; Ruby Pawankar; Musa Khaitov
Journal:  J Allergy Clin Immunol Pract       Date:  2018-10-05

Review 6.  The allergenic activity and clinical impact of individual IgE-antibody binding molecules from indoor allergen sources.

Authors:  Luis Caraballo; Rudolf Valenta; Leonardo Puerta; Anna Pomés; Josefina Zakzuk; Enrique Fernandez-Caldas; Nathalie Acevedo; Mario Sanchez-Borges; Ignacio Ansotegui; Luo Zhang; Marianne van Hage; Eva Fernández; Luisa Arruda; Susanne Vrtala; Mirela Curin; Hans Gronlund; Antonina Karsonova; Jonathan Kilimajer; Ksenja Riabova; Daria Trifonova; Alexander Karaulov
Journal:  World Allergy Organ J       Date:  2020-04-29       Impact factor: 4.084

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.